RxDoctor Payments DataLook up a doctor →

Diego Echeverri, MD

Nephrology · Lauderdale Lakes, FLNPI 1053308338

Payments from drug & device makers

$1,053,166in general payments, 2019–2025

Across 263 payments — averaging $4004.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$375K
  • AstraZeneca$349K
  • CSL Behring$218K
  • Boehringer Ingelheim$89K
  • Ardelyx, Inc.$11K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
  • plus $6K from 18 others

What the payments were for

  • Food & beverage$2,486100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,053,166 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$188,809
Medicare patients
209
Services billed
1,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol51$60,200
VeltassaPatiromer Calcium Sorbitex25$58,903
ProcritEpoetin Alfa76$46,179
KerendiaFinerenone21$27,087
RetacritEpoetin Alfa-Epbx56$22,692
SpsSodium Polystyrene Sulfon/Sorb18$6,156
Cinacalcet Hcl12$5,761
Sevelamer Carbonate14$4,414
Tacrolimus20$4,139
Calcitriol188$2,951
Calcium Acetate22$2,427
Nifedipine ErNifedipine30$875
Labetalol Hcl16$596
Losartan Potassium62$540
Allopurinol85$490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$348,548$60,20051 claims
BayerKerendia$324$27,08721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 756 nephrology providers in Florida.

Other nephrology in Lauderdale Lakes

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →